Organicell Regenerative Medicine, Inc.
OCELOTCHealthcare
$2.74
$-0.01(-0.27%)
Market Cap$19974944
P/E Ratio—
52W High$4.8
52W Low$0.896
Organicell Regenerative Medicine, Inc. (OCEL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OCEL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-10 | 2024-10 | 2023-10 | 2022-10 | 2021-10 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $5.20M | $4.62M | $4.56M | $6.49M | $5.60M |
| Cost of Revenue | $0.93M | $0.84M | $0.51M | $0.75M | $0.55M |
| Gross Profit | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M |
| Gross Margin %(computed) | 82.09% | 81.73% | 88.86% | 88.39% | 90.21% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.79M | $1.12M |
| G&A Expenses | $9.65M | $9.10M | $10.82M | $14.58M | $17.79M |
| Total Operating Expenses | $9.65M | $9.10M | $10.82M | $14.58M | $17.79M |
| Operating Income | ($5.39M) | ($5.32M) | ($6.77M) | ($8.84M) | ($12.74M) |
| Operating Margin %(computed) | -103.60% | -115.13% | -148.45% | -136.23% | -227.68% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.40M | $0.04M |
| Interest Expense | ($0.10M) | ($0.09M) | $0.43M | $0.40M | $0.04M |
| Income Before Tax | ($5.52M) | ($4.71M) | ($6.99M) | ($8.90M) | ($12.76M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.05M | $0.06M |
| Net Income | ($5.52M) | ($4.71M) | ($6.99M) | ($8.95M) | ($12.82M) |
| Net Margin %(computed) | -106.19% | -101.84% | -153.28% | -137.89% | -229.03% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.86 | $-0.74 | $-0.99 | $-1.57 | $-2.42 |
| Wtd Avg Shares | 6.41M | 6.34M | 7.03M | 5.69M | 5.30M |
| EBITDA | ($5.39M) | ($5.32M) | ($6.07M) | ($8.17M) | ($12.67M) |
| EBITDA Margin %(computed) | -103.60% | -115.13% | -133.14% | -125.80% | -226.28% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Organicell Regenerative Medicine, Inc. data
About Organicell Regenerative Medicine, Inc. (OCEL) Income Statement
Organicell Regenerative Medicine, Inc. (OCEL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, OCEL reported revenue of $0.01B, gross profit of $0.00B (gross margin 82.09%), and net income of ($0.01B) — a net profit margin of -106.19%.
Frequently asked questions
OCEL · 4 questionsOrganicell Regenerative Medicine, Inc. (OCEL) reported revenue of $0.01B for 2025, up 12.5% year-over-year.
OCEL revenueOCEL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08